Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jaktinib in Active Ankylosing Spondylitis
NCT05861102Phase 3Completed
- Sponsor
- Zelgen
- Start
- Jul 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of jaktinib in ankylosing spondylitis (AS), sponsored by Zelgen. Started Jul 2023; status: completed.
02
Drugs
jaktinib
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT05861102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05861102.